Associated tags: CE marking, Epigenomics AG, Liver cancer, FDA, DNA, Cancer, Food, Colorectal cancer, Epigenomics, ECX, OTCQX, Security (finance), News
Locations: TENNESSEE, NORTH AMERICA, DEUTSCHLAND, EPI
Retrieved on:
Wednesday, April 10, 2024
Finanzierung,
Randbedingung,
Wagniskapital,
Epigenomics,
Vertrag,
NEW,
Day,
LLC,
Verkauf,
Hauptversammlung,
Unternehmen,
Chance,
Vermarktung,
Bargeld,
Meilenstein,
Ablauf,
Patent,
Zukunft,
Aufwand,
Geschäftsjahr,
Kosten,
Forschung,
Entwicklung,
Restrukturierung,
Personalkosten,
Anstieg,
Vergleich,
Abfindung,
Bandbreite,
Aufwendung,
Zusammenhang
Retrieved on:
Wednesday, April 10, 2024
EUR,
Supervisory board,
AG,
Research,
Sale,
ECX,
HGB,
Epigenomics AG,
Bank statement,
News,
Investment,
Patent,
CSO,
Commercial code,
Lithium Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
Key Points:
- Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
- In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
- Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
- The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .
Retrieved on:
Thursday, February 15, 2024
Supervisory board,
Investment,
Supervision,
Epigenomics AG,
Epigenomics,
AG,
News,
ECX,
Annual,
WSB,
MBB,
Security (finance) Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.
Key Points:
- Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024.
- Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024.
- For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024.
- Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011.
Retrieved on:
Thursday, February 15, 2024
Epigenomics,
Frankfurt,
General,
Standard,
ECX,
Holding,
Fokus,
Beteiligung,
Bereich,
Blutuntersuchung,
Antragsrecht,
Vorstand,
Amtsgericht,
Charlottenburg,
Herr,
Hummeln,
Gesellschaft,
Doktor,
Gremium,
Bestellung,
Hauptversammlung,
Partner,
WSB,
Wolf,
Steuerberater,
Fachberater,
Steuerrecht,
Experte,
Aufsichtsrat,
Zusammenarbeit,
Expertise
Supervisory board,
Supervision,
CFO,
Housing,
KPMG,
Investment,
Epigenomics AG,
ECX,
News,
AG,
University,
Software Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory Board has appointed Mr. Hansjörg Plaggemars to the Executive Board effective February 1, 2024.
Key Points:
- Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory Board has appointed Mr. Hansjörg Plaggemars to the Executive Board effective February 1, 2024.
- Hansjörg Plaggemars (53) has more than 20 years of management experience in finance in various European companies.
- In 2014, Mr. Plaggemars joined Deutsche Balaton AG and founded his own consulting firm, Value Consult, in 2017.
- Dr. Helge Lubenow, Chairwoman of the Supervisory Board: „We are very pleased that Mr. Plaggemars with his extensive management experience and expertise in finance is joining Epigenomics AG.“
„I am looking forward to becoming part of the Epigenomics team,“ said Hansjörg Plaggemars.
Epigenomics,
Frankfurt,
General,
Standard,
ECX,
Holding,
Fokus,
Beteiligung,
Bereich,
Blutuntersuchung,
Aufsichtsrat,
Herr,
Wirkung,
Vorstand,
Finanzen,
Unternehmen,
Karriere,
KPMG,
Finance,
CFO,
Wirtschaftszweig,
Software,
Einzelhandel,
Elektronischer Handel,
Balaton,
Strand von Valu,
Funktion,
Projekt,
Hochschulabschluss,
Bamberg
Retrieved on:
Tuesday, January 30, 2024
Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024.
Key Points:
- Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024.
- The Supervisory Board will seek to find a suitable successor as member of the Company's Supervisory Board and arrange for his/her appointment by court order in accordance with the statutory provisions.
- The chairwoman of the Supervisory Board, Dr Helge Lubenow, thanks Dr Heikki Lanckriet (PhD) for his commitment and dedication to the company and its employees.
- 26.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Retrieved on:
Tuesday, January 30, 2024
Ph.D.,
Gremium,
Frankfurt,
General,
Standard,
ECX,
Amt,
Mitglied,
Gesellschaft,
Wirkung,
Aufsichtsrat,
Nachfolger,
Regelung,
Bestellung,
Frau,
Herr,
Doktor,
Engagement,
Einsatz,
Unternehmen,
Mitarbeiter
Retrieved on:
Tuesday, October 17, 2023
News,
USD,
EBITDA,
Supervisory board,
AG,
Epigenomics AG,
RTÉ Executive Board,
Patient,
Sale,
Epigenomics,
Security (finance),
Bank,
Rare-earth element As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.
Key Points:
- As a result, almost all of the Company's assets have been transferred to New Day Diagnostics.
- As part of the closing, the Company has received as consideration a cash payment of USD 0.5 million and an interest in New Day Diagnostics.
- Jens Ravens, Executive of Epigenomics AG: “The transfer of almost all assets now completed represents the closing of the sale which was overwhelmingly approved by our Extraordinary General Meeting on September 11, 2023.
- The adjustment results essentially from the income for the year 2023 from the contract with New Day Diagnostics.
Retrieved on:
Tuesday, October 17, 2023
